Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesTransplantSummaCare AlloMap Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    AlloMap and Heartsbreath Testing for Cardiac Allograft Rejection Monitoring

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and medical necessity for noninvasive monitoring of cardiac allograft rejection in commercial and Medicare members. It covers AlloMap genetic expression testing only when specified clinical criteria and testing-frequency limits are met and excludes Heartsbreath testing.

    Policy Summary
    PayerSummaCare
    PolicyAlloMap and Heartsbreath Testing for Cardiac Allograft Rejection Monitoring
    Policy CodePolicy N/A
    Change TypeRoutine review — no material change
    Effective DateAug 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for AlloMap when it is used instead of endomyocardial biopsy and document that all clinical criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    81595Covered AlloMap CPT code
    7AlloMap authorization criteria
    2–60 moPost-transplant testing interval
    81479

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not-covered molecular pathology code
    Not coveredHeartsbreath coverage status

    AlloMap and Heartsbreath Coverage Criteria

    AlloMap™ Initial Coverage Criteria

    AlloMap™ is covered instead of endomyocardial biopsy when the results will be used to determine the need for a subsequent endomyocardial biopsy to clarify rejection status and ALL of the following criteria are met.

    ALL of the following

    • The member has been under the care of the ordering provider within the past 30 days.
    • The member is not acutely symptomatic.
    • The member does not have recurrent rejection, defined as prior rejection with current signs or symptoms of rejection.
    • The member is not currently receiving 20 mg or more of daily oral prednisone.
    • The member has not received high-dose intravenous corticosteroids or myeloablative therapy within the past 21 days.
    • The member has not received blood products or hematopoietic growth factors within the past 30 days.
    • The member is not pregnant.

    AlloMap™ Testing Frequency

    Covered AlloMap™ testing frequency is based on the time elapsed since heart transplantation. The applicable interval below represents the maximum routine frequency unless otherwise supported by the policy criteria.

    Applicable post-transplant interval

    • The member is 2 to 6 months post-transplant: test every 2 to 4 weeks.
    • The member is 6 to 12 months post-transplant: test every 2 months.
    • The member is 12 to 24 months post-transplant: test every 3 months.
    • The member is 24 to 60 months post-transplant: test every 6 months.
    • The member is more than 60 months post-transplant: test every 12 months.

    Heartsbreath™ is not covered by SummaCare. The test is considered not medically necessary, experimental, and investigational for management of post-cardiac-transplantation rejection.

    AlloMap™ has limitations and should not be used as the basis for coverage in heart-transplant recipients who are acutely symptomatic; have recurrent rejection; have signs or symptoms of cardiac allograft dysfunction or hemodynamic compromise; are receiving 20 mg or more of daily oral prednisone; received high-dose intravenous corticosteroids or myeloablative therapy within the last 3 weeks; received a blood transfusion or hematopoietic growth factor affecting leukocytes within the last 30 days; or are pregnant.

    Heartsbreath™ is considered not medically necessary because there is insufficient evidence that breath testing for management of post-cardiac-transplantation rejection improves management or health outcomes. The Centers for Medicare & Medicaid Services determined that the evidence did not adequately define the test's technical characteristics or demonstrate improved health outcomes in Medicare beneficiaries; therefore, the test is not reasonable and necessary under section 1862(a)(1)(A) of the Social Security Act and is non-covered for services performed on or after December 8, 2008.

    Billing and Coding

    Covered CPT CodesCPTCovered
    81595Cardiology (heart transplant), mRNA, gene expression profiling by real-hyphentime quantitative PCR of 20 genes (11 content and 9 housekeeping), utilizing subfraction of peripheral blood, algorithm reported as a rejection risk score [Allomap]
    CPT Codes NOT coveredCPTNot Covered
    81479unlisted molecular pathology
    Daily oral prednisone
    Daily oral prednisone thresholdLess than 20 mg daily
    Coverage exclusionMembers currently receiving 20 mg or more of daily oral prednisone do not meet the AlloMap medical-necessity criteria.
    Applies toAlloMap testing covered instead of endomyocardial biopsy when all criteria are met.
    High-dose intravenous corticosteroids or myeloablative therapy
    Required lookbackHigh-dose intravenous corticosteroids or myeloablative therapy must not have been received in the past 21 days (3 weeks).
    Coverage exclusionRecent high-dose intravenous corticosteroid or myeloablative therapy excludes the member from the AlloMap medical-necessity criteria.

    Authorization and Denial Prevention

    Prior Authorization

    Authorize AlloMap only when criteria are met

    Obtain prior authorization for AlloMap when it is used instead of endomyocardial biopsy. Coverage requires that the results will be used to determine the need for a subsequent biopsy to clarify rejection status, and the request must document that all stated clinical criteria are met.

    Denial Risk

    Check AlloMap exclusion criteria before requesting

    AlloMap is not medically necessary when any exclusion criterion applies, including acute symptoms, recurrent rejection, pregnancy, or signs and symptoms of cardiac allograft dysfunction or hemodynamic compromise.

    • Do not request coverage if the member is receiving 20 mg or more of daily oral prednisone.
    • Confirm that high-dose intravenous corticosteroids or myeloablative therapy were not received within the past 21 days (3 weeks).

    Clinical Background

    Cardiac allograft rejection remains a frequent complication after heart transplantation. The incidence is highest during the first month after transplantation and declines thereafter.

    Key Terms

    AlloMap molecular expression testing
    Test typeA noninvasive assay that targets immune cells in peripheral blood involved in cardiac rejection.
    MeasurementMeasures patterns of activity of multiple genes to help diagnose and predict rejection.
    Rejection-risk scorePossible scores range from 0 to 40; higher scores correlate more strongly with histologic rejection.
    Heartsbreath
    Test typeA noninvasive breath test for markers that predict the probability of grade 3 rejection.
    Intended populationHeart transplant recipients who received their transplant within the preceding year.

    AlloMap Monitoring by Transplant Interval

    AlloMap molecular expression testing for cardiac allograft rejection monitoring
    Covered serviceAlloMap molecular expression testing for cardiac allograft rejection monitoring.
    Alternative to biopsyMay be covered instead of endomyocardial biopsy when results will determine whether a subsequent biopsy is needed to clarify rejection status.
    Medical-necessity requirementAll stated medical-necessity criteria must be met, including the applicable clinical exclusions.
    Testing intervalsTesting must follow the applicable schedule from 2 months through more than 60 months post-transplant: every 2 to 4 weeks, every 2 months, every 3 months, every 6 months, or every 12 months, respectively.
    Policy Summary
    PayerSummaCare
    PolicyAlloMap and Heartsbreath Testing for Cardiac Allograft Rejection Monitoring
    Policy CodePolicy N/A
    Change TypeRoutine review — no material change
    Effective DateAug 13, 2026
    Last ReviewAug 13, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for AlloMap when it is used instead of endomyocardial biopsy and document that all clinical criteria are met.
    SourceLink
    On This Page
    AlloMap and Heartsbreath Coverage CriteriaBilling and CodingAuthorization and Denial PreventionClinical BackgroundKey TermsAlloMap Monitoring by Transplant Interval
    Applies toAlloMap testing covered instead of endomyocardial biopsy when all criteria are met.
    Blood products or hematopoietic growth factors
    Required lookbackBlood products or hematopoietic growth factors must not have been received in the past 30 days.
    Coverage exclusionA blood transfusion or hematopoietic growth factor affecting leukocytes within the last 30 days excludes the member from the AlloMap medical-necessity criteria.
    Applies toAlloMap testing covered instead of endomyocardial biopsy when all criteria are met.
    AlloMap testing frequency
    2 to 6 months post-transplantEvery 2 to 4 weeks
    6 to 12 months post-transplantEvery 2 months
    12 to 24 months post-transplantEvery 3 months
    24 to 60 months post-transplantEvery 6 months
    More than 60 months post-transplantEvery 12 months
  1. Confirm that blood products or hematopoietic growth factors were not received within the past 30 days.
  2. Denial Risk

    Heartsbreath is non-covered

    Do not submit Heartsbreath for coverage. SummaCare considers it not covered, not medically necessary, experimental, and investigational; Medicare considers it non-covered because the evidence does not demonstrate improved health outcomes for Medicare beneficiaries.

    Denial Risk

    Match testing frequency to time since transplant

    AlloMap testing may be denied when the requested frequency exceeds the interval corresponding to the member’s time since transplant.

    • 2 to 6 months: every 2 to 4 weeks
    • 6 to 12 months: every 2 months
    • 12 to 24 months: every 3 months
    • 24 to 60 months: every 6 months
    • Greater than 60 months: every 12 months
    Coverage status
    SummaCare does not cover Heartsbreath; it is considered not medically necessary, experimental, and investigational.
    ISHLT acute cellular rejection grades
    Grade 1RMild: interstitial and/or perivascular infiltrate with up to one focus of myocyte damage.
    Grade 2RModerate: at least two foci of infiltrate with associated myocyte damage.
    Grade 3RSevere: diffuse infiltrate with multifocal myocyte damage, with or without edema, hemorrhage, or vasculitis.